Navigation Links
Sunesis in Medical Technology

SARcode and Sunesis Announce Start of Phase 1 Clinical Trial in Ocular Inflammatory Diseases

SOUTH SAN FRANCISCO, Calif., Sept. 5 /PRNewswire-FirstCall/ -- SARcode Corporation, a private company focused on small molecule LFA-1 inhibitors to treat inflammatory diseases, and Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS) today announced SARcode's initiation of a Phase 1 clinical trial of ...

Sunesis Pharmaceuticals Announces Presentation of Voreloxin Clinical Data in Patients with Acute Myeloid Leukemia at the 50th Annual Meeting of the American Society of Hematology

... SAN FRANCISCO , Dec. 7 /PRNewswire-FirstCall/ -- sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS ) today anno...erated. Conference Call Information sunesis management will host a conference call on Tuesday,...ors and Media - Calendar of Events" section of the sunesis website at www.sunesis.com . The webcast will be...

Sunesis Announces New Data on Voreloxin for Acute Myeloid Leukemia To Be Presented at ASH

...NCISCO, Calif., Dec. 1 /PRNewswire-FirstCall/ -- sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS ), a biophar...60 Conference Call Information sunesis management will host a conference call to discuss ...ors and Media - Calendar of Events" section of the sunesis website at www.sunesis.com . The webcast will be...

Sunesis Pharmaceuticals Presents Clinical Trial Data of Voreloxin in Patients with Acute Myeloid Leukemia and Ovarian Cancer at the Chemotherapy Foundation Symposium

...SH," said Daniel Swisher, Chief Executive Officer, sunesis Pharmaceuticals. "Our goal is to advance voreloxin...been escalated to 75 mg/m2 dosed every four weeks. sunesis expects to complete enrollment of the 75 mg/m2 coh...ar survival rates at less than 30 percent. About sunesis Pharmaceuticals ...

Sunesis Pharmaceuticals Presents Data from Clinical Trials of Voreloxin (formerly SNS-595) in Patients with Acute Myeloid Leukemia at the 13th Congress of the European Hematology Association

...n an acute need for new treatment options. About sunesis Pharmaceuticals sunesis is a clinical-stage biopharmaceutical company focu...or the treatment of solid and hematologic cancers. sunesis has built a highly experienced cancer drug develop...

Sunesis Pharmaceuticals Focuses Resources on Development of Voreloxin (Formerly SNS-595)

... In conjunction with this strategic restructuring, sunesis expanded the company's late-stage development lead...tently well tolerated in multiple clinical trials. sunesis is currently conducting Phase 2 clinical trials of...nation with cytarabine for the treatment of AML. sunesis continues ongoing trials in its earlier-stage clin...

Sunesis Pharmaceuticals Presents Updated Clinical Data From Ongoing Phase 2 Trial of Voreloxin (Formerly SNS-595) in Ovarian Cancer Patients at the 44th ASCO Annual Meeting

...ofile demonstrated in this Phase 2 clinical trial, sunesis increased the dose of voreloxin in this trial to 6...een observed. Based on voreloxin's safety profile, sunesis recently announced that the protocol for the ongoi...25 percent to 75 mg/m(2) given once every 28 days. sunesis expects to enroll approximately 30 patients at thi...

Sunesis Pharmaceuticals to Present Interim Clinical Data From Voreloxin (Formerly SNS-595) Ovarian Cancer Trial at 44th ASCO Annual Meeting and Acute Myeloid Leukemia Trials at 13th EHA Congress

...will be available following each conference on the sunesis corporate website at http://www.sunesis.com . About Sunesis' Oncology Programs sunesis has built a rich portfolio of product candidates i...al in patients with advanced solid tumors. About sunesis Pharmaceuticals ...

Sunesis Pharmaceuticals Initiates Phase 2 Clinical Trial of Voreloxin (SNS-595) in Acute Myeloid Leukemia

...a from this trial indicate clear clinical benefit, sunesis could initiate a pivotal trial in this highly unde...medical conference toward the end of this year." sunesis previously reported promising results from its Pha...lerated weekly dose of 72 mg/m2 was established. sunesis also announced today that voreloxin has been accep...

Sunesis Pharmaceuticals Reports Data from Nonclinical Studies of SNS-032 at the Annual Meeting of the American Association for Cancer Research

...by the MMRC Validation Team, in collaboration with sunesis scientists, of SNS-032 in human myeloma cell lines...cell lymphoma cell lines" (Abstract #756). About sunesis Pharmaceuticals sunesis is a clinical-stage biopharmaceutical company focu...

Sunesis Pharmaceuticals to Present Non-Clinical Data at the Annual Meeting of the American Association for Cancer Research

...ch (AACR) being held April 12-16 in San Diego, CA. sunesis has built a portfolio of product candidates in onc...ibit Hall B-F, San Diego Convention Center About sunesis Pharmaceuticals sunesis is a clinical-stage biopharmaceutical company focu...

Sunesis Pharmaceuticals Reports Positive Interim Data for SNS-595 Single-Agent Activity in Platinum-Resistant Ovarian Cancer

...ar survival rates at less than 30 percent. About sunesis Pharmaceuticals sunesis is a clinical-stage biopharmaceutical company focu...rapeutics for oncology and other serious diseases. sunesis has built a broad product candidate portfolio thro...

Sunesis Pharmaceuticals to Present Data on Two Product Candidates at the 49th Annual Meeting of the American Society of Hematology

... Center in Atlanta, Georgia. On December 10, 2007, sunesis management will host a conference call for investo... a.m. to 7:00 p.m. Conference Call Information sunesis management will host a conference call to discuss ...ors and Media - Calendar of Events" section of the sunesis website at http://www.sunesis.com . Please log on...

Sunesis Pharmaceuticals Reports Preliminary SNS-595 Activity in Ovarian Cancer Clinical Trial at AACR-NCI-EORTC International Conference

...- /ADVANCE FOR RELEASE AT 3:30 P.M. EDT, TODAY/ -- sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS ), a clinical...nt progressed within 60 days of initial response. sunesis plans to enroll approximately 55 patients in this ...hirty-one patients have been enrolled to date, and sunesis expects to complete enrollment and present additio...

Sunesis Pharmaceuticals Commences Clinical Trials of SNS-595 and SNS-314

...ug-resistant models. About SNS-314 Discovered by sunesis using the company's discovery platform, SNS-314 is...le in the abnormal proliferation of tumors. About sunesis Pharmaceuticals sunesis is a clinical-stage biopharmaceutical company focu...

Sunesis Pharmaceuticals Presents SNS-314 Aurora Kinase Inhibitor Data Showing Broad Anti-Tumor Activity, Dosing Flexibility

..., Calif., March 20, 2007 /PRNewswire-FirstCall/ -- sunesis Pharmaceuticals, Inc. , presented non-clinical dat...er Therapies (TAT 2007) meeting held in Amsterdam, sunesis researchers presented results showing SNS-314's an...of this year. About Sunesis' Oncology Programs sunesis has built a rich portfolio of product candidates i...

Sunesis Pharmaceuticals to Present Data at the Annual Meeting of the American Association for Cancer Research

..., Calif., April 13, 2007 /PRNewswire-FirstCall/ -- sunesis Pharmaceuticals, Inc. today announced that the com... 7, board #1. About Sunesis' Oncology Programs sunesis has built a rich portfolio of product candidates i...hibition of the cell-cycle and survival signaling. sunesis is currently conducting Phase 2 clinical trials in...

Sunesis Presents Data Supporting SNS-032's Potential Anticancer Activity in Multiple Myeloma at the American Association for Cancer Research Meeting

...l lymphoma. Non-clinical studies were conducted by sunesis evaluating SNS-032's mechanism of action and in vi...ce apoptosis. About Sunesis' Oncology Programs sunesis has built a rich portfolio of product candidates i...hibition of the cell cycle and survival signaling. sunesis is currently conducting Phase 2 clinical trials in...

Sunesis Pharmaceuticals to Present Data at the 12th Congress of the European Hematology Association

...O, Calif., June 01, 2007 /PRNewswire-FirstCall/ -- sunesis Pharmaceuticals, Inc. today announced that the com...session. About Sunesis' Oncology Programs sunesis has built a rich portfolio of product candidates i...hibition of the cell-cycle and survival signaling. sunesis is currently conducting Phase 2 clinical trials in...

Sunesis Pharmaceuticals Reports Positive Data From Studies of Two Anti-Cancer Agents, SNS-595 and SNS-032, at the 12th Congress of the European Hematology Association

...O, Calif., June 11, 2007 /PRNewswire-FirstCall/ -- sunesis Pharmaceuticals, Inc. presented positive data from...odels while sparing normal hematopoietic recovery. sunesis plans to initiate a Phase 1b clinical trial of SNS...NS-032 to Flavopirodol In a second presentation, sunesis reported the results of studies evaluating its cyc...

Sunesis Pharmaceuticals to Present at the C. E. Unterberg, Towbin Emerging Growth Conference

...O, Calif., July 03, 2007 /PRNewswire-FirstCall/ -- sunesis Pharmaceuticals, Inc. today announced that Eric Bj...ss the webcast of the presentation by visiting the sunesis website at sunesis website for two weeks until July 26, 2007. Optio...
Other Tags
(Date:9/30/2014)... burning is published today in the first authoritative scientific ... tensions on both sides of the grouse moor management ... on the Ecohydrology of River basins) project has shown ... to support red grouse populations for gun sports, has ... physical properties, river water chemistry and river ecology. , ...
(Date:9/30/2014)... salmon, and strawberries all have in common? Unlike ... chromosomes and are diploid, these organisms are all polyploid, ... watermelon and salmon have 3 and 4 sets of ... might seem surprising, in fact most plant species are ... a century ago, but only recently, with the development ...
(Date:9/30/2014)... team of environmental scientists and engineers, led by ... a three-year, $5.25 million grant from the U.S. ... Research to make a direct positive impact on ... and disposal of radioactive contaminants. , "Understanding the ... dealing with environmental aspects of nuclear technologies is ...
Breaking Biology News(10 mins):Grouse moor burning causes widespread environmental changes 2Gene doubling shapes the world: Instant speciation, biodiversity, and the root of our existence 2Gene doubling shapes the world: Instant speciation, biodiversity, and the root of our existence 3Gene doubling shapes the world: Instant speciation, biodiversity, and the root of our existence 4Researchers get $5.25 million to advance nuclear technologies in South Carolina 2
(Date:10/1/2014)... 01, 2014 First Warning Systems, a ... cellular changes throughout the body, announced the company is ... address the company’s breadth of upcoming product releases. The ... screening technology. , “Our initial focus will be an ... detects abnormal circadian cellular changes over time,” said Rob ...
(Date:10/1/2014)... (PRWEB) October 01, 2014 ... networking and relationship-marketing firm, announced today the ... Executive® and Project of the Year Awards ... makers representing organizations in financial services, commercial, ... large-scale technology endeavors that address key issues ...
(Date:10/1/2014)... (PRWEB) October 01, 2014 Join the more ... Eating Disorder Treatment Center’s first ever charity golf tournament to ... people with eating disorders who cannot afford treatment. The tournament ... Club in Eureka, Mo. , The day-long event starts ... A reception and award dinner will begin at 5 p.m. ...
(Date:10/1/2014)... Beverly Hills licensed Clinical Psychologist and ... 20 years of private practice in her Beverly Hills ... achieve greater joy and fulfillment in their relationships. Dr. ... and suggestions for anyone who suspects they are in ... it or not, it’s not always easy to know ...
(Date:10/1/2014)... Innovations announces the upcoming airing of Innovations with ... 20, 2014 at 7:30 a.m. EST/PT via Discovery Channel. ... scenes to learn about Break the Cycle’s comprehensive dating ... help and information Break the Cycle provides to teens ... abuse, how to navigate the legal system, and provides ...
Breaking Medicine News(10 mins):Health News:First Warning Systems Changes Name to Cyrcadia Health to Better Reflect Core Competency and Goals of Company 2Health News:First Warning Systems Changes Name to Cyrcadia Health to Better Reflect Core Competency and Goals of Company 3Health News:First Warning Systems Changes Name to Cyrcadia Health to Better Reflect Core Competency and Goals of Company 4Health News:T.E.N. Announces Nominees for the 2014 ISE® North America Awards; People’s Choice Award voting now open to industry at large 2Health News:T.E.N. Announces Nominees for the 2014 ISE® North America Awards; People’s Choice Award voting now open to industry at large 3Health News:T.E.N. Announces Nominees for the 2014 ISE® North America Awards; People’s Choice Award voting now open to industry at large 4Health News:T.E.N. Announces Nominees for the 2014 ISE® North America Awards; People’s Choice Award voting now open to industry at large 5Health News:T.E.N. Announces Nominees for the 2014 ISE® North America Awards; People’s Choice Award voting now open to industry at large 6Health News:T.E.N. Announces Nominees for the 2014 ISE® North America Awards; People’s Choice Award voting now open to industry at large 7Health News:Project HEAL Benefit Golf Tournament Gaining Momentum 2Health News:Project HEAL Benefit Golf Tournament Gaining Momentum 3Health News:Prominent Beverly Hills Psychologist Dr. Kathleen Mojas Celebrating 20 Years in Private Practice Identifies Common Warning Signs That You May Be In a Toxic Relationship. 2Health News:Prominent Beverly Hills Psychologist Dr. Kathleen Mojas Celebrating 20 Years in Private Practice Identifies Common Warning Signs That You May Be In a Toxic Relationship. 3Health News:Innovations to Explore Breakthroughs in Health and Wellness in Upcoming Episode Airing Monday, October 20, 2014 via Discovery Channel 2
Other Contents